Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 18/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643791 | 0.78 | HCAR1 (0.48) | HCAR1 | |
| SCHEMBL28766407 | 0.71 | NPC1 (0.63) | CA12CA9 | |
| SCHEMBL3669160 | 0.70 | MAPK14 (0.45) | CA12CA9 | |
| SCHEMBL28936229 | 0.69 | HSD17B10 (0.59) | HCAR1 | |
| SCHEMBL16981653 | 0.69 | PDE9A (0.60) | — | |
| SCHEMBL4672868 | 0.68 | RAB9A (0.67) | CA12CA9 | |
| SCHEMBL14905764 | 0.67 | PDE3B (0.39) | HCAR1CA12CA9 | |
| SCHEMBL4700339 | 0.66 | MGLL (0.44) | HCAR1 | |
| SCHEMBL3672555 | 0.64 | PDE10A (0.47) | — | |
| SCHEMBL5579309 | 0.64 | HCAR1 (0.36) | HCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846944-B2 | Pyrazolo-pyridinone compounds and methods of use thereof | AMGEN INC. (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2152704-A1 | PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | Amgen, Inc (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090012299-A1 | Pyrazolo-pyridinone compounds and methods of use thereof | AMGEN INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008137176-A1 | PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012299-A1 | Pyrazolo-pyridinone compounds and methods of use thereof | MAPK1, MAP3K1, MAP4K2 | HCAR1 714/4885CA12 4805/4885CA9 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.